If you have been on a stable therapeutic dose (0.5 mg, 1 mg or 2 mg weekly) for several weeks and experience no reduction in appetite, your healthcare provider may need to reassess your treatment plan
The pharmacokinetic argument is solid (the math is well-understood for any GLP-1 with a long half-life), but efficacy and safety in a split protocol haven't been formally tested
It depends on factors like how much weight is lost, individual body composition, and whether the person is maintaining muscle mass through exercise
Lower distribution friction, direct-channel access, and platform economics favor the transparent-pricing model that Cost Plus Drugs proved viable
If you follow these steps, you can feel more sure about what you are doing
Many patients experience serious side effects, including gallbladder complications